Interpretation of Relative Efficacy and Effectiveness for Influenza Vaccines.

Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America Pub Date : 2022-08-24 DOI:10.1093/cid/ciab1016

Nathaniel M Lewis, Jessie R Chung, Timothy M Uyeki, Lisa Grohskopf, Jill M Ferdinands, Manish M Patel

{"title":"Interpretation of Relative Efficacy and Effectiveness for Influenza Vaccines.","authors":"Nathaniel M Lewis, Jessie R Chung, Timothy M Uyeki, Lisa Grohskopf, Jill M Ferdinands, Manish M Patel","doi":"10.1093/cid/ciab1016","DOIUrl":null,"url":null,"abstract":"Background: Relative vaccine effectiveness (rVE) are metrics commonly reported to compare absolute VE (aVE) of 2 vaccine products.Methods: Estimates of rVE for enhanced influenza vaccines (eIV) vs standard inactivated influenza vaccine (IIV) have been assessed across different seasons, influenza-specific endpoints, and nonspecific endpoints (eg, all-cause cardiovascular hospitalizations). To illustrate the challenges of comparability across studies, we conducted a scenario analysis to evaluate the effects of varying absolute VE (aVE) of IIV (ie, as compared with placebo) on the interpretation of rVE of eIV vs IIV.Results: We show that estimates of rVE might not be comparable across studies because additional benefits commensurate with a given estimate of rVE are dependent on the aVE for the comparator vaccine, which can depend on factors such as host response to vaccine, virus type, and clinical endpoint evaluated.Conclusions: These findings have implications for interpretation of rVE across studies and for sample size considerations in future trials.","PeriodicalId":10421,"journal":{"name":"Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America","volume":" ","pages":"170-175"},"PeriodicalIF":0.0000,"publicationDate":"2022-08-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"11","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/cid/ciab1016","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 11

Abstract

Background: Relative vaccine effectiveness (rVE) are metrics commonly reported to compare absolute VE (aVE) of 2 vaccine products.

Methods: Estimates of rVE for enhanced influenza vaccines (eIV) vs standard inactivated influenza vaccine (IIV) have been assessed across different seasons, influenza-specific endpoints, and nonspecific endpoints (eg, all-cause cardiovascular hospitalizations). To illustrate the challenges of comparability across studies, we conducted a scenario analysis to evaluate the effects of varying absolute VE (aVE) of IIV (ie, as compared with placebo) on the interpretation of rVE of eIV vs IIV.

Results: We show that estimates of rVE might not be comparable across studies because additional benefits commensurate with a given estimate of rVE are dependent on the aVE for the comparator vaccine, which can depend on factors such as host response to vaccine, virus type, and clinical endpoint evaluated.

Conclusions: These findings have implications for interpretation of rVE across studies and for sample size considerations in future trials.

查看原文本刊更多论文

流感疫苗的相对疗效和有效性的解释。

背景:相对疫苗有效性(rVE)是比较两种疫苗产品绝对有效性(aVE)的常用指标。方法:在不同季节、流感特异性终点和非特异性终点(如全因心血管住院)评估强化流感疫苗(eIV)与标准灭活流感疫苗(IIV)的rVE估计。为了说明跨研究可比性的挑战，我们进行了情景分析，以评估IIV的不同绝对VE (aVE)(即与安慰剂相比)对eIV与IIV的rVE解释的影响。结果:我们表明，rVE的估计值可能无法在研究之间进行比较，因为与给定rVE估计值相称的额外益处取决于比较疫苗的aVE，这可能取决于宿主对疫苗的反应、病毒类型和评估的临床终点等因素。结论:这些发现对跨研究的rVE解释和未来试验的样本量考虑具有启示意义。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America

自引率

0.00%

发文量